Gainers
- Sundial Growers SNDL stock rose 9.2% to $0.55 during Tuesday's after-market session. At the close, Sundial Growers's trading volume reached 4.9 million shares. This is 4.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.1 billion.
- IN8bio INAB shares moved upwards by 8.21% to $4.15. The market value of their outstanding shares is at $77.8 million.
- Doximity DOCS shares increased by 7.03% to $53.25. Trading volume for this security closed at 374.5K, accounting for 14.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.9 billion. As per the press release, Q3 earnings came out today.
- Vaccinex VCNX stock moved upwards by 4.57% to $1.6. The market value of their outstanding shares is at $63.2 million.
- Assertio Holdings ASRT shares increased by 4.16% to $2.75. The market value of their outstanding shares is at $122.7 million.
- Surgalign Holdings SRGA stock rose 3.43% to $0.63. The market value of their outstanding shares is at $92.9 million.
Losers
- Zosano Pharma ZSAN stock fell 33.4% to $0.32 during Tuesday's after-market session. Trading volume for this security closed at 671.8K, accounting for 31.3% of its average full-day volume over the last 100 days. The company's market cap stands at $37.2 million.
- Nuvectis Pharma NVCT stock fell 7.92% to $5.82. The company's market cap stands at $68.7 million.
- Varex Imaging VREX stock fell 4.64% to $25.49. The company's market cap stands at $1.0 billion. As per the news, the Q1 earnings report came out today.
- Dermata Therapeutics DRMA stock declined by 3.65% to $1.32. The company's market cap stands at $10.9 million.
- Durect DRRX shares fell 3.48% to $0.71. The market value of their outstanding shares is at $161.5 million.
- Karyopharm Therapeutics KPTI stock decreased by 3.3% to $7.92. The company's market cap stands at $598.3 million. As per the news, the Q4 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.